Overview of Breast Cancer and Implications of Overtreatment of Early-Stage Breast Cancer: An Indian Perspective

Gouri Shankar Bhattacharyya, MD, PhD, MRCP1; Dinesh C. Doval, MD, DM2; Chirag J. Desai, MD, DM3; Harit Chaturvedi, MS, MCh4; Sanjay Sharma, MS, MCh5; and S.P. Somashekhar, MS, MCh6

The prevalence and mortality of breast cancer is increasing in Asian countries, including India. With advances in medical technology leading to better detection and characterization of the disease, it has been possible to classify breast cancer into various subtypes using markers, which helps predict the risk of distant recurrence, response to therapy, and prognosis using a combination of molecular and clinical parameters. Breast cancer and its therapy, mainly surgery, systemic therapy (anticancer chemotherapy, hormonal therapy, targeted therapy, and immunotherapy), and radiation therapy, are associated with significant adverse influences on physical and mental health, quality of life, and the economic status of the patient and her family. The fear of recurrence and its devastating effects often leads to overtreatment, with a toxic cost to the patient financially and physically in cases in which this is not required. This article discusses some aspects of a breast cancer diagnosis and its impact on the various facets of the life of the patient and her family. It further elucidates the role of prognostic factors, the currently available biomarkers and prognostic signatures, and the importance of ethnically validating biomarkers and prognostic signatures.

JCO Global Oncol 6:789-798. © 2020 by American Society of Clinical Oncology
Creative Commons Attribution Non-Commercial No Derivatives 4.0 License

BREAST CANCER PREVAILABLE, SUBTYPES, AND TREATMENT

Epidemiology

Breast cancer is the most frequently diagnosed cancer and the most frequent cause for cancer-related deaths in women worldwide. Globally, breast cancer accounted for 2.08 million out of 18.08 million new cancer cases (incidence rate of 11.6%) and 626,679 out of 9.55 million cancer-related deaths (6.6% of all cancer-related deaths) in 2018. In India, breast cancer has surpassed cancers of the cervix and the oral cavity to be the most common cancer and the leading cause of cancer deaths. In 2018, 162,468 new cases of breast cancer were diagnosed, representing 27.7% of all new cancers among Indian women and 11.1% of all cancer deaths.

The epidemiology of breast cancer differs significantly in Indian women when compared with the Western population. The median age of women at the time of diagnosis of breast cancer is approximately 61 years in the Western world, with the peak age being 60 to 70 years; however, in India, a higher proportion of patients with breast cancer tend to be premenopausal, and the peak age is between 40 and 50 years. This is of concern because early-onset breast cancer is more aggressive and has a poorer prognosis than late-onset breast cancer. Furthermore, 60% to 70% of all patients with breast cancer in the United States are diagnosed with stage 1 disease, whereas only approximately 1% to 8% of Indian women present with stage 1 disease. Although only approximately 10% of women in the United States present with stage IV disease, in India this number is approximately 6% to 24%, with approximately 29% to 52% of Indian women presenting at stage III. Finally, although the incidence of breast cancer is rising globally, mortality associated with breast cancer is decreasing in the West but is increasing in India.

Overview of Subtypes and Stages of Breast Cancer

The modern classification of breast cancer is based on immunohistochemistry (IHC), histopathologic features, and molecular characterization. The 2 most frequent histologic subtypes of invasive breast cancer are invasive ductal carcinoma and invasive lobular carcinoma (80% to 85% and 10% to 15% of all cases, respectively). Other histologic cancer subtypes compose the remaining < 1% of invasive breast cancers. IHC characterization of breast cancer is important for determining the treatment of breast cancer and for predicting prognosis. IHC characterization depends on the expression of biomarkers such as estrogen receptor (ER), progesterone receptor (PR), and human...
epidermal growth factor receptor 2 (HER2). ER and PR expression of \( \geq 1\% \) is found in approximately 75% of patients with breast cancer who are considered to have hormone receptor (HR)–positive disease.\(^{12}\) Furthermore, approximately 15% to 30% of breast cancer cases amplify or overexpress HER2, as measured by IHC.\(^{13}\) Tumors not expressing ER and PR, and also not overexpressing HER2, termed triple-negative breast cancer (TNBC), tend to be aggressive and are associated with higher metastasis and recurrence rates than other breast cancer subtypes.\(^{14,15}\) In India, the prevalence of TNBC is estimated at 31%, much higher than the Western prevalence of 12% to 17%.\(^{16}\)

The staging of breast cancer into stages 0, 1, 2 and 3 is based traditionally on the TNM model. Keeping in mind the importance of molecular characterization, the American Joint Committee on Cancer’s Cancer Staging Manual, 8th edition, expanded breast cancer staging in 2017 by integrating prognostic biomarkers (such as histologic tumor grade, ER, PR, HER2, and multigene test-based risk prediction) with the conventional anatomic TNM staging. This has now resulted in a large number of combinations of anatomic, clinical, and prognostic breast cancer stages.\(^{17,18}\)

**Breast Cancer: Current Treatment**

Surgery is the mainstay of treatment of the early stages of breast cancer, and it ranges from lumpectomy to modified radical mastectomy. Surgery typically includes sentinel lymph nodes (LN) dissection for staging the extent of spread into the axilla. Adjuvant treatment using pharmacotherapy and radiotherapy is required for treating residual micrometastatic disease and reducing the recurrences rate. In 2013, the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer suggested that breast cancer may be classified into 5 subtypes: luminal A, luminal B with HER2 negative, luminal B with HER2 positive, HER2-enriched, and basal-like: triple negative (Table 1).\(^{19}\)

### Breast Cancer: Prognosis and Recurrence

Breast cancer prognosis largely depends on the stage at diagnosis and the HR status. Early breast cancer (stages 0 and I) generally has a favorable prognosis, and the 5-year survival rate is close to 100%. The 5-year survival rates dramatically decline with higher stages of breast cancer, with the rates for stages II, III, and IV being approximately 93%, 72%, and 22%, respectively.\(^{7}\) The 5-year survival rates are the highest for ER-positive and PR-positive cases, and lowest for ER-negative and PR-negative cases, across all stages of breast cancer.\(^{20}\)

Breast cancer recurrences represent a major source of cancer-related deaths.\(^{21}\) On average, 8% to 10% of breast cancer cases present with locoregional recurrences after

| Subtype                        | Type of Therapy                                      |
|-------------------------------|------------------------------------------------------|
| Luminal A                     | Endocrine therapy                                    |
| Luminal B with HER2 negative   | Endocrine therapy; chemotherapy added for most patients|
| Luminal B with HER2 positive   | Chemotherapy plus anti-HER2 therapy + endocrine therapy|
| HER2 enriched                 | Chemotherapy plus anti-HER2 therapy                  |
| Basal-like (triple negative)  | Chemotherapy                                         |

**NOTE.** Data adapted from Goldhirsch A et al.\(^{19}\) Abbreviation: HER2, human epidermal growth factor receptor 2.
surgery, and approximately 11% to 30% of patients develop distant metastases. The recurrence risk is higher in cancers that are advanced, of a high grade, HER2/neu positive, or TNBC cases. During the first 5 years of diagnosis, ER-negative breast cancers have a higher recurrence risk than do ER-positive breast cancers; the risk seems to equalize between both subtypes after 15 years of diagnosis. However, the recurrence risk in HR-negative cancers is confined mostly to the first 5 years after diagnosis. This is also seen in HER2-positive tumors. Conversely, HR-positive cancers generally tend to display late recurrences for at least 15 years. The recurrence rates in TNBCs are generally higher than in HR-positive cancers. The sites of recurrence and metastasis also depend on the type of breast cancer. Clinical factors favoring an increased relapse risk include higher tumor grade, large tumor size, axillary LN involvement, and HR-negative cancers. LN involvement is the most important prognostic factor for recurrences, and axillary LN-positive disease is associated with a 4-8 times higher mortality rate than LN-negative disease. Before initiating treatment of recurrent breast cancer, rebiopsy and restaging is necessary. Recurrent breast cancer treatment depends on the disease stage, the site and type of recurrence, and the time to recurrence, and it generally follows the principles of treatment of systemic therapy with or without surgery and radiation.

IMPACT OF CANCER TREATMENT ON PATIENTS WITH BREAST CANCER

Breast Cancer Treatment: Adverse Effects

Breast cancer surgery and the associated sentinel LN biopsy result in transient physical discomforts such as pain and numbness in the chest wall, axilla, and breast, and arm edema. Cosmetic concerns after total mastectomy can be addressed by breast conserving surgery and breast reconstruction surgeries. However, this is often associated with poor body image and other psychosexual problems. Anticancer drugs are used to treat almost all patients with breast cancer. Breast cancer mortality has decreased drastically over the past few decades, and this drop in the mortality rate could be accounted for by an increased use of adjuvant chemotherapy over this period, leading to improved survival of patients with breast cancer. Adjuvant chemotherapy is thus a life-saving intervention for a patient with breast cancer. However, different subtypes and stages of breast cancer have different recurrence risks. Hormone-positive HER2-negative breast cancer that is detected early is associated with a 10% to 15% risk of distant recurrence over 10 years, and an only 2% to 3% absolute chemotherapy benefit, which is approximately the same as the risk of fatal, life-threatening, or permanently changing toxicities. In such patients, because the benefits do not outweigh the risk of adjuvant chemotherapy, the associated adverse effects (AEs) and long-term consequences of anticancer treatment continue to remain a major concern for patients as well as for clinicians. The most often observed chemotherapy-related AEs are nausea and vomiting, oral and GI mucositis leading to malabsorption, anorexia, weight loss, anemia and other related manifestations, hypersensitivity, and peripheral neuropathy. Approximately 90% of patients with breast cancer experience at least 1 AE. The most frequent chemotherapy-related AEs observed in Indian patients with breast cancer include alopecia, nail discoloration, dysgeusia, and anorexia. The AEs caused by breast cancer chemotherapy bring about emotional trauma, which may be augmented by a lack of proper professional support.

Even though drugs are used and other approaches are taken to overcome the AEs of cancer chemotherapy, they are often incompletely effective. Furthermore, these interventions often do not address the long-term consequences of cancer treatment. Treatment of the AEs also adds to the financial burden of the disease. A study performed in a health care setting in the United States estimated that chemotherapy-related AEs resulted in a large incremental expenditure of USD 1,271 per patient annually. The sum of the AEs and the additional financial burden caused by these AEs results in worsening of the quality of life (QoL) of the patient with cancer.

With improvements in the technology of radiation therapy, serious complications after radiotherapy are rarely seen these days. The most frequently reported AEs after radiotherapy for breast cancer include skin reactions, including edema, fibrosis, erythema, changes in pigmentation, and ulcerations, and problems caused by inflammation, including itching, warmth, dryness, and burning of skin. Incidental radiation exposure of the heart, lungs, and contralateral breast may occasionally result in complications in these organs, especially in patients who receive radiotherapy after mastectomy.

Economic Impact of Breast Cancer Treatment

Breast cancer carries a significant economic burden. The adverse economic impact of breast cancer has been reported extensively from various parts of the globe. A 2018 systematic review of 20 studies reported that breast cancer treatment costs increased with a higher stage of cancer at diagnosis. Thus, earlier diagnosis of breast cancer can lower treatment costs. In India, although no study has accurately described the economic burden of the disease among Indian patients, the costs associated with breast cancer are expected to be high because of the high proportion of out-of-pocket (OOP) expenditure for treatment, leading to catastrophic payments, which are caused by overdependence on the private health care sector and poor health insurance uptake. A 2016 study from Punjab reported that 36.23% of the total breast cancer treatment cost was for drugs (Fig 1). Obtaining treatment from the private sector was costlier than from the public sector, and the costs increased with older age and a higher stage of cancer at diagnosis.
another study, the average total OOP expenditure for breast cancer in 2014 was Indian Rupee (INR) 29,066 in public sector hospitals and INR 84,320 in private sector hospitals (USD 1715.82 and USD 4977.56 at 2014 purchasing power parity, respectively). Furthermore, nearly one half of low-income households (rural more than urban) used distressed means (defined as borrowings, sale of assets, and contribution from friends and relatives as first major source) for financing treatment expenditures caused by breast cancer. Finally, more than one half of patients from low-income households spent > 20% of their annual household expenditure on breast cancer treatment, leading to catastrophic payments. An analysis of 3 public insurance schemes for anticancer treatment in India published in 2018 revealed inconsistency in the selection of reimbursed treatments. The reimbursed amount was found to be insufficient to cover the total cancer chemotherapy costs, leading to an average budget shortage of up to 43% for breast cancer treatment. Thus, breast cancer can be expected to result in extreme financial hardships in Indian families.

**Impact on QoL and Family**

Even though breast cancer treatment is lifesaving, the physical AEs of cancer treatment and the treatment costs reduce the QoL of breast cancer survivors, which is already lowered with the diagnosis of cancer. The QoL decline is worse if the patients with breast cancer have certain comorbidities (hypertension, diabetes, and arthritis), receive chemotherapy, have less social support, or have more unmet needs. In the Indian scenario, a woman is conventionally expected to carry out different roles in the family, including being a wife, a mother, and a mother-in-law, each having some significant responsibility in the family; during the course of breast cancer treatment, the ability of the affected woman to completely fulfill these responsibilities may be hampered. A study from 2019 revealed that nearly 43% of patients with breast cancer had to struggle to meet the expenses associated with breast cancer. Furthermore, a male member of the family was the prime decision maker, and the caregiver was generally an immediate family member. Approximately 90% of patients admitted to facing social embarrassment because of the disease.

**BREAST CANCER OVERTREATMENT AND ITS PREVENTION: ROLE OF PROGNOSTIC MARKERS**

**Breast Cancer Overtreatment and Its Implications**

A concerning issue with any cancer is the problem of cancer overtreatment and the accompanying adverse outcomes. Breast cancer overtreatment can put the recipients at the receiving end of all the AEs of cancer treatment discussed earlier. Every effort should be taken to prevent cancer overtreatment by identifying those patients in whom the administration of these risky treatment modalities can be safely avoided. Furthermore, cancer overtreatment can drain the limited health resources in developing countries.

A major factor predisposing to overtreatment of cancer is fear: fear on the patient’s side of dying as a result of cancer, and fear on the doctor’s side of missing a serious diagnosis and its consequences. However, this fear does not always warrant treatment with toxic drugs: breast cancer was detected at autopsy in up to 39% of middle-aged women in the United States who died as a result of something else. Clearly, this section of asymptomatic patients with breast cancer did not require chemotherapy. However, the case might have been different had they been informed that they had breast cancer. This highlights the importance of restricting breast cancer treatment to patients who clearly need it, thereby preventing breast cancer overtreatment. At the same time, denying treatment to those who clearly need it...
it (undertreatment) is equally devastating, and should be avoided.

Preventing Breast Cancer Overtreatment

Preventing breast cancer overtreatment can be achieved in 2 different ways. The first is by diagnosing breast cancer in its earlier stages through the screening of healthy women at a high risk of developing the disease, by using modalities such as mammography and ultrasonography. Such a diagnosis at an early stage can result in the initiation of early treatment, which avoids many of the adverse outcomes that are associated with initiating more aggressive treatment strategies at later stages of the disease. However, over-enthusiastic screening can also lead to another unwanted outcome in the form of overdiagnosis. In fact, the estimated prevalence of breast cancer overdiagnosis has been up to 54% in some populations, which highlights the extent of the problem.56 Such overdiagnosis may enhance the problem of overtreatment instead of lowering it, because of the overenthusiastic administration of treatment on demand by patients who are scared by the diagnosis of cancer.57 Another problem documented with early screening for breast cancer is bias, such as healthy volunteer bias, length-biased sampling, and lead-time bias.58

The second way to prevent breast cancer overtreatment is by predicting the recurrence risk of the disease. If this can be achieved reliably, then administration of adjuvant chemotherapy can be limited to only those patients at a higher risk of developing such recurrences, thereby avoiding overtreatment in patients who might not need it. At present, the risk assessment tools that are popularly used in India include IHC4, luminal A/B subtyping, and PREDICT. Fifty-eight percent of Indian oncologists surveyed as part of a recent study reported using the online tool PREDICT to help decide on a course of adjuvant treatment.59 Using molecular profiling and gene expression testing, it has become possible to predict the future behavior of breast cancer, thereby marking the beginning of the era of precision medicine in the disease.57 This concept of identifying patients with breast cancer who could be safely spared chemotherapy was considered the topmost priority area in a 2007 Web-based survey of multidisciplinary cancer experts from around the world.60

Role of Prognostic Markers

With the increasing interest in the human genome, many genes influencing different stages of breast cancer have been identified, measured, and profiled to find out whether a correlation exists between gene expression and cancer recurrence risk. This has led to the introduction of several multigene assays for predicting prognosis and outcomes in patients with breast cancer (Table 2). The status of a patient with respect to these prognostic markers is intended to guide clinical decision making about initiating adjuvant chemotherapy and/or endocrine therapy after initial treatment of the breast cancer, depending on the risk of distant recurrence of the cancer.51,62 In the United States, Oncotype DX is the most widely used among these breast cancer assays, followed by MammaPrint.63 Other prognostic markers discussed in the literature include MapQuant Dx,64 the Theros breast cancer index,65 the Rotterdam signature,66 and the Invasiveness gene signature.67

| TABLE 2. Some Prognostic Markers for Breast Cancer |
| Prognostic Marker/Index/Assay | Nature | Details |
| Oncotype DX68 | Multigene molecular tool | Using a RT-PCR–based 21-gene molecular, this tool estimates the likelihood of distant recurrence in patients with node-negative, tamoxifen-treated breast cancer |
| MammaPrint69 | Multigene molecular tool | 70-gene molecular assay predicting prognosis after 5 and 10 years on the basis of recurrences |
| Endopredict70 | Multigene molecular tool | Quantification of mRNA levels of 8 genes by qRT-PCR to predict 10-year distant recurrence rate |
| Prosigna PAM5071 | Multigene molecular tool | 50-gene–based molecular assay predicting risk of recurrence of breast cancer |
| MD Anderson Prognostic index72 | Multiparameter index | Using clinical nodal status, residual pathologic tumor size, pattern of residual disease, and lymphovascular space invasion, this index predicts risk of locoregional recurrence after neoadjuvant chemotherapy before breast surgery |
| NHS PREDICT73 | Multiparameter online tool | Online tool using tumor size, type, LN involvement, and markers including ER, HER2, and Ki67 for predicting prognosis in patients with breast cancer after surgery |
| Online! Adjuvant74 | Multiparameter online tool | Online tool using patient demographics, tumor staging, and ER status for estimating prognosis in patients with breast cancer after receiving adjuvant chemotherapy |

Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; LN, lymph nodes; qRT-PCR, quantitative one-step reverse transcriptase polymerase chain reaction; RT-PCR, reverse transcriptase polymerase chain reaction.
Many of these prognostic markers have been validated in clinical trials, predominantly in the Western world setting. The most significant clinical trials are the Trial Assigning Individualized Options for Treatment (Rx; TAILORx), performed in the United States for validating Oncotype DX,75 and the Microarray in Node-Negative Disease May Avoid Chemotherapy (MINDACT) trial, performed in the European Union for validating MammaPrint.93 Furthermore, ASCO included some of these prognostic markers (such as Oncotype DX, MammaPrint, Endopredict, and Prosigna PAM50) in its 2017 clinical practice guidelines for predicting whether patients with breast cancer derive benefit from adjuvant chemotherapy.76 Through pharmacoeconomic modeling studies performed around the globe, it has been proven that despite increasing the overall cost, the use of prognostic markers can significantly improve the quality-adjusted life-years and are therefore cost effective.77,83 At the same time, there are concerns about the improper use and misinterpretation of these markers leading to breast cancer undertreatment.84 Prognostic biomarkers commercially available in India as of March 2020 include ER, PR, HER2, Ki67, Oncotype DX, MammaPrint, Endopredict, and Prosigna.85

**Importance of Ethnical Validation of Prognostic Markers**

Breast cancer is a heterogeneous disease, and global ethnic variations in the outcomes of breast cancer are well known, as discussed earlier.10 Even within the United States, ethnic variations are repeatedly observed wherein breast cancer incidence is lower but the outcomes are worse among Black women when compared with White women.86,87 In a recent study, it was reported that young non-Hispanic Black women with breast cancer in the United States had significantly higher mortality and morbidity rates than did women of other ethnicities.88 Significant ethnic variations relating to incidence, relapse-free survival, and outcomes of breast cancer have been described in the United Kingdom89,90 and South East Asia91 as well. Various reasons have been proposed for this difference, and the most accepted ones are differences in the levels of p53 expression and differences in the incidence of the mutated proto-oncogene HRAS1 allele.92,93

Although differences are noticed within the different ethnicities of a single country, it is not surprising to expect major differences with respect to epidemiology and outcomes of breast cancer among patients around the world. A 2015 study compared frozen breast cancer specimens from patients in China and Italy and concluded that the prevalence of the luminal A breast cancer subtype was significantly lower in the Chinese specimens.94 Despite the lack of such comparative studies between patients with breast cancer from the West and from other countries, it is not unreasonable to assume that such differences in various facets of the disease may exist and that the basis for such differences may be at the genetic or molecular level. This assumption gains immense significance when we consider using prognostic markers, which are largely validated in the Western setting, for making clinical decisions for initiating or withholding treatment options in patients with breast cancer in the Indian setting.

In the recent past, Indian oncologists have had divided opinions about using prognostic markers developed in the West for making treatment decisions in breast cancer, and by far the most important reason for such resistance has been economic.95 However, we believe that the more important question to be asked before using a prognostic marker for making a treatment decision should be whether the marker has been validated in a comparable ethnic and racial setting. Recent opinions strongly advocate validation of diagnostic and prognostic study findings to suit the population undergoing treatment, rather than blindly adopting Western findings, and this is especially needed in Asian settings where the burden of breast cancer is expected to increase tremendously in the near future.96 In fact, some of the prognostic markers discussed earlier have fared poorly when tested in women from different ethnicities. For example, a TAILORx subgroup analysis revealed that there were ethnic differences within the study population, and that Black women who were participants of TAILORx study had worse clinical outcomes when compared with the non-Black women, despite similar 21-gene assay results of the Oncotype DX marker and comparable systemic therapy.97

Furthermore, MammaPrint was found to have a different ratio of low- to high-risk patients in Japanese and Korean cohorts compared with European cohorts. This led to the hypothesis that gene disparities between Asian and White people could be contributing to the observed differences and that a recalibration of the cutoff may be required before such prognostic tests can be used in Asian settings.98,99 Adjuvant! Online was also found to display inaccurate results when applied to prognosticate Asian patients with breast cancer.100-102 Thus, although prognostic markers are essential to prevent breast cancer overtreatment, using prognostic markers that are ethnically validated is equally essential. Such concerns have been raised by Indian oncologists recently as well.103 The Asian Breast Cancer Cooperative Group 2019 consensus document advocates evidence-based yet flexible and individualized use of international treatment guidelines in Asia because these guidelines are based on data from predominantly non-Asian postmenopausal women, whereas young Asian women have distinctive clinicopathologic characteristics.103 None of the popularly used prognostic markers discussed previously (including Oncotype DX and MammaPrint) have been ethnically validated in Indian patients with breast cancer, and hence, using these markers to make clinical decisions for continuing or withholding chemotherapy for patients with breast cancer might not be entirely appropriate or accurate. However, an indigenously developed prognostic signature, the CanAssist Breast (CAB; Oncostem...
The CAB is a machine-learning–based proteomic risk classifier. It combines 5 biomarkers (CD44, ABCC4, ABCC11, N-cadherin, and pan-cadherin) through IHC and 3 clinicopathologic parameters (tumor size, tumor grade, and node status) to calculate a “CAB risk score” that classifies Asian Indian patients with breast cancer into having a low risk or high risk of developing distant recurrence in 5 years. The CAB has been validated analytically, demonstrating the robustness of the test, and has been validated clinically in a retrospective cohort of primarily Asian Indian patients with breast cancer. A 2019 study compared the CAB risk stratification of 455 patients with breast cancer from across India with that by Adjuvant! Online. The proportion of patients with high recurrence risk as per the CAB was nearly one half the number given by Adjuvant! Online (29% vs 62.4%). Furthermore, the CAB categorized 36.6% of Adjuvant! Online high-risk patients into low risk, thereby enabling the treating physicians to avoid overtreating these patients with chemotherapy. Even though validation in a prospective trial is pending, the CAB seems to be a reliable and cost-effective alternative to the established prognostic markers that have been developed in Western settings and have not been validated in the Indian setting, for predicting the risk of recurrence of breast cancer and for taking clinical decisions about starting or withholding chemotherapy for Indian patients with the disease.

Breast cancer has significant adverse impacts on the physical health, mental health, QoL, and economic status of the patient and her family, which are further accentuated by overtreatment. To prevent the overtreatment of breast cancer, there is a definite role for prognostic markers to identify women who are at a low risk of developing distant recurrences of the disease and thus can be safely spared the administration of chemotherapy. Despite the availability of many such prognostic markers around the world, none of them have been validated in the Indian setting, and they are expected to be inaccurate if they are relied on for taking the crucial decision of withholding chemotherapy for patients with breast cancer. Prognostic markers such as the CAB, validated in Indian settings, are the need of the hour. Additional validation in prospective clinical trials can strengthen the definitive role of such prognostic markers in the treatment of breast cancer in Indian women.

**AFFILIATIONS**

1Salt Lake City Medical Centre, Kolkata, West Bengal, India
2Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
3Vedanta Institute of Medical Sciences, Ahmedabad, Gujarat, India
4Max Institute of Cancer Care, New Delhi, India
5Asian Cancer Institute, Somaiya Ayurvihar, Mumbai, Maharashtra, India
6Department of Surgical Oncology, Manipal Comprehensive Cancer Center, Manipal Hospital, Bengaluru, India

**CORRESPONDING AUTHOR**

S.P. Somashekhar, MS, MCh, Department of Surgical Oncology, Manipal Comprehensive Cancer Center, Manipal Hospital, No. 98, HAL Airport Rd, Bengaluru – 560017, India; e-mail: somashekhar.sp@manipalhospitals.com.

**SUPPORT**

Supported by Oncostem Diagnostics, Bengaluru, India, and by editorial services from MarksMan Healthcare Communications, India.

**AUTHOR CONTRIBUTIONS**

Conception and design: Gouri Shankar Bhattacharyya, Dinesh C. Doval, Chirag J. Desai, S. P. Somashekhar
Administrative support: Dinesh C. Doval
Provision of study material or patients: Dinesh C. Doval
Collection and assembly of data: Gouri Shankar Bhattacharyya, Dinesh C. Doval, Harit Chaturvedi, Sanjay Sharma
Data analysis and interpretation: Gouri Shankar Bhattacharyya, Dinesh C. Doval, Harit Chaturvedi, Sanjay Sharma
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors

**AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST**

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/go/site/misc/authors.html.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

**Gouri Shankar Bhattacharyya**

Stock and Other Ownership Interests: Vicus Therapeutics
Honoraria: Mylan, Biocon, Cipla, Intas, India
Consulting or Advisory Role: Vicus Therapeutics, Mylan, Biocon, Cipla, Zuventus, OncoStem Diagnostics
Research Funding: Vicus Therapeutics
Speakers’ Bureau: Biocon, Novartis, Cipla, Meda, Intas, Boehringer Ingelheim, AstraZeneca, OncoStem Diagnostics

**Chirag J. Desai**

Honoraria: Pfizer, Roche India, Eli Lilly, Biocon, Mylan, Novartis
Speakers’ Bureau: Eli Lilly
Sanjay Sharma

**Acknowledgment**

We thank MarksMan Healthcare Communications, India, for assistance in the preparation of this article.
42. Luengo-Fernandez R, Leal J, Gray A, et al: Economic burden of cancer across the European Union: A population-based cost analysis. Lancet Oncol 14:1165-1174, 2013
43. Vondeling GT, Menezes GL, Dvortsin EP, et al: Burden of early, advanced and metastatic breast cancer in the Netherlands. BMC Cancer 18:262, 2018
44. Gauthier G, Gagnon-Sanschagrin P, Guérin A, et al: Economic burden of HR+/HER2- metastatic breast cancer among adult premenopausal women. Adv Ther 35:503-514, 2018
45. Roine E, Färkkilä N, Sintonen H, et al: Costs in different states of breast cancer. Anticancer Res 39:353-359, 2019
46. Sun L, Legood R, Dos-Santos-Silva I, et al: Global treatment costs of breast cancer by stage: A systematic review. PLoS One 13:e0207993, 2018
47. Dang A, Valtchev B N: Can Health Technology Assessment (HTA) provide a solution to tackle the increasing health-care expenditure in India? Indian J Public Health 60:138-141, 2016
48. Jain M, Mukherjee K: Economic burden of breast cancer to the households in Punjab, India. Int J Med Public Health 6:13-18, 2016
49. Rajpal S, Kumar A, Joe W: Economic burden of cancer in India: Evidence from cross-sectional nationally representative household survey. 2014. PLoS One 13:e0193520, 2018
50. Haisma G, Patel H, Gurumurthy P, et al: Access to anti-cancer drugs in India: Is there a need to revise reimbursement policies? Expert Rev Pharmacoecon Outcomes Res 18:289-296, 2015
51. Jones SM, LaCroix AZ, Li W, et al: Depression and quality of life before and after breast cancer diagnosis in older women from the Women’s Health Initiative. J Cancer Surviv 9:620-629, 2015
52. Ho PJ, Gernaat SAM, Hartman M, et al: Health-related quality of life in Asian patients with breast cancer: A systematic review. BJM Open 8:e020512, 2018
53. Alexander A, Kaluwe R, Prabhu JS, et al: The impact of breast cancer on the patient and the family in Indian perspective. Indian J Palliat Care 25:66-72, 2019
54. Bhatt JR, Klotz L: Overtreatment in cancer - Is it a problem? Expert Opin Pharmacother 17:1-5, 2016
55. Welch HG, Black WC: Using autopsy series to estimate the disease “reservoir” for ductal carcinoma in situ of the breast: How much more breast cancer can we find? Ann Intern Med 127:1023-1028, 1997
56. Elmore JG, Fletcher SW: Overdiagnosis in breast cancer screening: Time to tackle an underappreciated harm. Ann Intern Med 156:536-537, 2012
57. Houssami N: Overdiagnosis of breast cancer in population screening: Does it make breast screening worthless? Cancer Biol Med 14:1-8, 2017
58. Crosswell JM, Ransohoff DF, Kramer BS: Principles of cancer screening: Lessons from history and study design issues. Semin Oncol 37:202-215, 2010
59. Batra A, Patel A, Gupta VG, et al: Oncotype DX: Where does it stand in India? J Glob Oncol 5:1-2, 2019
60. Dowsett M, Goldhirsch A, Hayes DF, et al: International Web-based consultation on priorities for translational breast cancer research. Breast Cancer Res 9:R81, 2007
61. Tirada N, Aujero M, Khorjekar G, et al: Breast cancer tissue markers, genomic profiling, and other prognostic factors: A primer for radiologists. Radiographics 38:1902-1920, 2018
62. Albain KS, Paik S, van’t Veer L: Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Breast 18:S141-S145, 2009
63. Marchionni L, Afsari B, Geman D, et al: A simple and reproducible breast cancer prognostic test. BMC Genomics 14:336, 2013
64. Sotiriou C, Wirapati P, Loi S, et al: Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98:262-272, 2006
65. Ma XJ, Salunga R, Dahya S, et al: A five-gene molecular grade index and HOXB13:1L178R are complementary prognostic factors in early stage breast cancer. Clin Cancer Res 14:2601-2608, 2008
66. Wang Y, Klijn JG, Zhang Y, et al: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365:671-679, 2005
67. Liu R, Wang X, Chen YG, et al: The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 356:217-226, 2007
68. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004
69. Cardoso F, van’t Veer LJ, Bogaerts J, et al: 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 375:717-729, 2016
70. Filipits M, Rudas M, Jakesz R, et al: A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 17:6012-6020, 2011
71. Walden B, Storhoff J, Nielsen T, et al: Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. BMC Med Genomics 8:54, 2015
72. Chen AM, Meric-Bernstam F, Hunt KK, et al: Breast conservation after neoadjuvant chemotherapy. Cancer 103:689-695, 2005
73. Wishart GC, Azzato EM, Greenberg DC, et al: PREDICT: A new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res 12:R1, 2010 [Erratum: Breast Cancer Res 12:401, 2010]
74. Olivotto IA, Bajとき DK, Ravdin PM, et al: Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 23:2716-2725, 2005
75. Sparano JA, Gray RJ, Makower DF, et al: Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 375:717-729, 2016
76. Krop I, Ismaila N, Andre F, et al: Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer. American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol 35:2838-2847, 2017
77. Kip M, Montebon H, Steuten L: Long-term cost-effectiveness of Oncotype DX® versus current clinical practice from a Dutch cost perspective. J Comp Eff Res 4:433-445, 2015
78. Yang M, Rajan S, Issa AM: Cost-effectiveness of gene expression profiling for early stage breast cancer: A decision-analytic model. Cancer 118:5163-5170, 2012
79. Kondo M, Hashi SL, Yamanaka T, et al: Economic evaluation of the 21-gene signature (Oncotype DX) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (UBCRG-TR03). Breast Cancer Res Treat 127:739-749, 2011
80. Hornberger J, Chien R, Krebs K, et al: US insurance program’s experience with a multigene assay for early-stage breast cancer. J Oncol Pract 7:e38s-e45s, 2011
81. Klang SH, Hamerman A, Liebermann N, et al: Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization. Value Health 13:381-387, 2010
82. Retel VP, Joore MA, Knauer M, et al: Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer. Eur J Cancer 46:1382-1391, 2010
83. Tsoi DT, Inoue M, Kelly CM, et al: Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer. Oncologist 15:457-465, 2010

84. Matikas A, Foukakis T, Swain S, et al: Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures. Are we there yet? Ann Oncol 30:1044-1050, 2019

85. Aggarwal S, Vaid A, Ramesh A, et al: Practical consensus recommendations on management of HR+ve early breast cancer with specific reference to genomic profiling. South Asian J Cancer 7:96-101, 2018

86. Chlebowski RT, Chen Z, Anderson GL, et al: Ethnicity and breast cancer: Factors influencing differences in incidence and outcome. J Natl Cancer Inst 97:439-448, 2005

87. Bowen RL, Stebbing J, Jones L: A review of the ethnic differences in breast cancer. Pharmacogenomics 7:935-942, 2006

88. Ren JX, Gong Y, Ling H, et al: Racial/ethnic differences in the outcomes of patients with metastatic breast cancer: Contributions of demographic, socioeconomic, tumor and metastatic characteristics. Breast Cancer Res Treat 173:225-237, 2019

89. Gathani T, Ali R, Balkwill A, et al: Ethnic differences in breast cancer incidence in England are due to differences in known risk factors for the disease: Prospective study. Br J Cancer 110:224-229, 2014

90. Copson E, Maishman T, Gerty S, et al: Ethnicity and outcome of young breast cancer patients in the United Kingdom: The POSH study. Br J Cancer 110:230-241, 2014

91. Bhoo-Pathy N, Hartman M, Yip CH, et al: Ethnic differences in survival after breast cancer in South East Asia. PLoS One 7:e30995, 2012

92. Jones BA, Kasl SV, Howe CL, et al: African-American/White differences in breast carcinoma: p53 alterations and other tumor characteristics. Cancer 101:1293-1301, 2004

93. Januszewski A, Tanna N, Stebbing J: Ethnic variation in breast cancer incidence and outcomes—the debate continues. Br J Cancer 110:4-6, 2014

94. Huang X, Dugo M, Callari M, et al: Molecular portrait of breast cancer in China reveals comprehensive transcriptomic likeness to Caucasian breast cancer and low prevalence of luminal A subtype. Cancer Med 4:1016-1030, 2015

95. Rajagopal B: Genomic tests for cancer split oncologists. The Economic Times, June 27, 2018. https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/genomic-tests-for-cancer-split-oncologists/articleshow/64756787.cms?from=mdr

96. Bhoo-Pathy N, Yip CH, Hartman M, et al: Breast cancer research in Asia: Adopt or adapt Western knowledge? Eur J Cancer 49:703-709, 2013

97. Albain K, Gray RJ, Sparano JA, et al: Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer: Results from the TAILORx trial. 2018 San Antonio Breast Cancer Symposium, San Antonio, TX, December 4-8, 2018 (abst GS4-07)

98. Ishibashi K, Morinaga Y, Komoike Y, et al: Clinical utility of the 70-gene MammaPrint profile in a Japanese population. Jpn J Clin Oncol 40:508-512, 2010

99. Na KY, Kim KS, Lee JE, et al: The 70-gene prognostic signature for Korean breast cancer patients. J Breast Cancer 14:33-38, 2011

100. Bhoo-Pathy N, Yip CH, Hartman M, et al: Adjuvant! Online is overoptimistic in predicting survival of Asian breast cancer patients. Eur J Cancer 48:982-989, 2012

101. Jung M, Choi EH, Nam CM, et al: Application of the Adjuvant! Online model to Korean breast cancer patients: An assessment of prognostic accuracy and development of an alternative prognostic tool. Ann Surg Oncol 20:2615-2624, 2013

102. Yao-Lung K, Dar-Ren C, Tsai-Wang C: Accuracy validation of Adjuvant! Online in Taiwanese breast cancer patients—a 10-year analysis. BMC Med Inform Decis Mak 12:108, 2012

103. Yeo W, Ueno T, Lin CH, et al: Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression. Breast Cancer Res Treat 177:549-559, 2019

104. Ramkumar C, Buturovic L, Malpani S, et al: Development of a novel proteomic risk-classifier for prognostication of patients with early-stage hormone receptor-positive breast cancer. Biomark Insights 13:117727191889100, 2018

105. Attuluri AK, Serkal CPV, Gunda A, et al: Analytical validation of CanAssist-Breast: An immunohistochemistry based prognostic test for hormone receptor positive breast cancer patients. BMC Med 19:249, 2019

106. Bakre MM, Ramkumar C, Attuluri AK, et al: Clinical validation of an immunohistochemistry-based CanAssist-Breast test for distant recurrence prediction in hormone receptor-positive breast cancer patients. Cancer Med 8:1755-1764, 2019

107. Sankaran S, Dixit JB, Prakash SV, et al: CanAssist Breast impacting clinical treatment decisions in early-stage HR+ breast cancer patients: Indian scenario. Indian J Surg Oncol 2019

108. Chakraborty S, Wadasadawala T, Ahmed R, et al: Breast cancer demographics, Types and management pathways: Can Western algorithms be optimally used in Eastern countries? Clin Oncol (R Coll Radiol) 31:502-509, 2019